Recipharm AB (Jordbro) and Flamel Technologies SA (Lyon) announce today that they have entered into a long term collaboration and signed an agreement whereby Recipharm will purchase Flamel’s development and manufacturing facility located in Pessac, France. Recipharm will significantly expand its pharmaceutical development capacity and technical capabilities to provide easier access for development services to its French and other customers. Recipharm will also provide development and manufacturing support to Flamel under a long term services agreement. This new partnership allows Flamel to retain access to the development and manufacturing capabilities of Pessac and gain the possibility to use any of Recipharm’s other facilities for the development or manufacture of their proprietary pipeline. Recipharm will also assume development and manufacturing agreements with other companies and as well as an agreement providing a royalty income. Highlights · The purchase price for the assets is €10.6m plus working capital. · In a separate transaction, Recipharm will also make an investment of €10.5m in newly issued Flamel Shares which corresponds to approximately 2.3% of Flamel shares. · Recipharm and Flamel have entered into a long term service agreement. · Recipharm will assume several new development and manufacturing contracts and relationships. · Recipharm will assume a contract from Flamel which will generate an ongoing royalty income. · Recipharm and Flamel have agreed to negotiate a contract with the intention of further enhancing the economic benefits to both companies whereby Recipharm will incorporate Flamel’s drug delivery technologies into its contract development business. · Recipharm has an option to negotiate with Flamel for the European rights to any product that Flamel plans to license for sale in the European market. · Recipharm’s European development reach and capabilities will be enhanced by the transaction providing easier access especially for French customers. · The deal adds new technical capabilities for spray granulation and spray coating. · Accretive to profit and EPS. · Closing is expected before the end of 2014. Speaking about the transaction, Thomas Eldered, CEO of Recipharm said “I am delighted that we are now entering into a strategic partnership with Flamel and taking over a first class development and manufacturing facility in France. Development services is in many respects a ‘local’ business so having another centre in addition to Sweden should allow us to increase this aspect of our business. Our investment into Flamel is also particularly exciting given the clear strategy that they are pursuing. The commitment we are both showing towards each other is a clear demonstration of the bright future we see for this relationship. We are looking forward to supporting Flamel to fulfill their ambitions to develop and manufacture new products based on their proprietary technology”. Mike Anderson, CEO of Flamel added “Flamel’s primary objective is the development of products using the company’s proprietary drug delivery platforms. The sale of the Pessac facility frees us from the time-consuming task of running a contract development manufacturing facility,” He added “This sale allows us to continue development of our proprietary products using our current drug delivery technologies at the Pessac facility and the option to utilize Recipharm’s commercial manufacturing capabilities elsewhere. Given Recipharm’s expertise, the investment in Flamel’s stock is a welcome endorsement of Flamel’s anticipated success moving forward.” About Pessac The Pessac facility is located in Bordeaux, France. It is a modern, fully compliant GMP (FDA and ANSM-approved) facility for the development and manufacturing of pharmaceuticals and has around 115 employees. The facility manufactures Flamel’s Medusa and Micropump proprietary drug delivery technologies.The facility is 44.000m2 with 9.500m2 development and manufacturing space. It is equipped with amongst other things three spray -coating machines, warehousing, analytical and QC laboratories, equipment for polymer synthesis. Transaction Rationale Significantly increased scale and reach in pharmaceutical development. · Combined development business will become a major player in the industry. · Provide a strong platform for development sales in France/Southern Europe complementing the Sweden based facility Strategic partnership with Flamel. · Long term service agreement for the development of Flamel products. Important new development and manufacturing contracts assumed with other companies including a royalty income stream. Improved offering. · Adds new technologies for spray granulation and spray coating. · Increases scale and reach of European development business. Transaction terms Consideration and financing. · The transaction purchase price is €10.6m plus the value of the inventory. · Concurrent investment in Flamel Technologies SA of €10.5 million, corresponding to approximately 2.3% of Flamel shares. · Financing already available Timetable The closing of the transaction is expected to be before year end 2014. There are no material conditions to closing. For further information please visit www.recipharm.com or contact: Thomas Eldered, Thomas.eldered@recipharm.com, +46 8 602 52 10 Björn Westberg, CFO, bjorn.westberg@recipharm.com, +46 8 602 46 20 This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of NASDAQ Stockholm. This information was submitted for publication on 27 November, 2014, at 8:30 am CET. About Recipharm Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry based in Sweden employing some 2,100 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma through to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.2 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com (http://file///C:/Users/Thomas/AppData/Local/Microsoft/Windows / Temporary%20Internet%20Files/Content.Outlook/FZHEQOEB/visit%20www.recipharm.com) . Recipharm has retained Ramboult-Legoater and Obermayer Rebmann Maxwell & Hippel LLP as advisors in this transaction. About Flamel Technologies Flamel Technologies SA's (NASDAQ: FLML) business model is to blend high-value internally developed products with its leading drug delivery capabilities. The company markets Bloxiverz™ (neostigmine methylsulfate) in the USA and manufactures Micropump-based microparticles under FDA-audited GMP guidelines for Coreg CR® (carvedilol phosphate), marketed in the USA by GlaxoSmithKline. The Company has a proprietary pipeline of niche specialty pharmaceutical products, while its drug delivery platforms are focused on the goal of developing safer, more efficacious formulations of drugs to address unmet medical needs. Its pipeline includes chemical and biological drugs formulated with its Micropump® (and its applications to the development of liquid formulations LiquiTime® and of abuse-deterrent formulations Trigger Lock™) and Medusa™ proprietary drug delivery platforms. Several Medusa-based products have been successfully tested in clinical trials. The Company is headquartered in Lyon, France and has operations in St. Louis, Missouri, USA, and manufacturing facilities in Pessac, France. Additional information may be found at www.flamel.com. Recipharm AB (publ) Corporate identity number 556498-8425 Address Lagervägen 7, SE-136 50 Jordbro, Sweden Telephone 46 8 602 52 00 Fax 46 8 81 87 03, www.recipharm.com
Recipharm acquires Flamel Technologies facility and extend
Top 10 Most Recent News Articles
Precision Metal Forming Is Industry's Quiet Backbone
A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...
Continue Reading
Five Films Put Modern Infrastructure Under a Lens
Most infrastructure only earns a thought when it breaks, and that is precisely the nerve these films are trying to touch. Nicely Done Productions has released the final five installments of its ten-part Threads of Connectivity documentary series, hosted on National Geographic's global digital platform. The subjects are illycaffè, Cargill, Honeywell Aerospace, Western...
Continue Reading
Why Lear’s PACE Award Matters Beyond Seat Warmers Today
Seat foam and wiring seldom make investors sit upright, yet Lear has managed to turn that unglamorous corner of the vehicle into something worth watching. The company’s Modular Thermal Comfort Systems just won a 2026 Automotive News PACE Award, a respected supplier-industry nod for innovation and business performance. Awards alone do not pay anybody’s bills, and I...
Continue Reading
Century Complete Tests Conway Demand Near Myrtle Beach
Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...
Continue Reading
Dar Global’s $700M Qatar Bet Leans on Trump Branding
Luxury property launches rarely arrive quietly, and this one came wrapped in Palm Beach ceremony, championship golf and a very loud brand name. Dar Global has formally introduced Trump International Simaisma, Qatar, a QAR 2.5 billion development—about $700 million—alongside The Trump Organization. That is a meaningful chunk of real estate ambition, not a little side...
Continue Reading
TORM Rejects Hafnia's No-Premium Merger Pitch Again
A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...
Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster
A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...
Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment
A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...
Continue Reading
Tonum and Euvita Link Supplements to Personalized Care
Muscle loss has become the awkward footnote in the GLP-1 weight-loss boom, and Tonum Health is trying to put that concern nearer the center of the care conversation. Its newly announced partnership with euvita health places Tonum's supplements and functional nutrition products inside a physician-led platform built around biomarker testing, hormone and peptide therapy,...
Continue Reading
Another Nine's A9OS Puts Software at Center of Golf
A golf simulator chain is trying to turn the boring plumbing into its sharpest club. Another Nine’s A9OS is not merely a booking widget dressed up for a franchise brochure; it is meant to run the whole 24/7 operation, from payments and door access to cameras, simulator support and guest help. That ambition deserves attention because this is exactly where a staff-free...
Continue ReadingTop 5 Most Recently Viewed Articles
Bunzl Reports Strong Performance and Strategic Acquisitions
Bunzl Reports Strong Growth and Strategic Acquisitions Recently, Bunzl plc (OTC: BZLFY), a leading international distribution and services group, showcased its resilience with a reported 5.4% increase in group revenue at constant exchange rates for the most recent quarter. This growth, noted from the quarter ending June 30, 2024, presents a nuanced picture alongside a...
Continue Reading
Experience RainFocus: INSIGHT 2026 Event Essentials
Exciting Announcement for INSIGHT 2026 Event RainFocus unveils the theme "Connecting Journeys" for its highly anticipated event. INSIGHT 2026 is set to happen Nov. 5, featuring a focus on creating seamless experiences throughout customer journeys. Connecting Journeys: The Theme for 2026 RainFocus, known for its innovative event marketing platform, has officially announced...
Continue Reading
UK Economic Activity Declines as Job Cuts Accelerate Amid Budget Fallout
UK Economic Activity Experiences Significant Slowdown As the year comes to a close, UK business activity has shown a significant slowdown, with employers now forced to cut jobs at an alarming rate. Recent findings from a Purchasing Managers' Index (PMI) survey have painted a bleak picture of the economic landscape, prompting concerns about the future of various sectors....
Continue Reading
Irwin W. Aronson Honored Among Influential Leaders Over 50
Irwin W. Aronson Recognized for Contributions to Public Service Irwin W. Aronson has recently received a notable honor from City & State Pennsylvania. He has been named one of the esteemed Fifty Over 50 honorees, a tribute to individuals whose trailblazing work significantly shapes the future of their communities. This recognition showcases Aronson’s dedication and...
Continue Reading
Axiom Medical Welcomes Kevin Campbell as CFO to Lead Growth
Axiom Medical Welcomes Kevin Campbell as New CFO Axiom Medical, a leader in occupational health services, has made a significant move by appointing Kevin Campbell as its new Chief Financial Officer. This decision reflects the company’s dedication to improving its financial management and service delivery. Kevin officially took on this important role on September 1,...
Continue Reading